In the first study of 297 patients with breast cancer who were genotyped for polymorphisms in CYP2D6,[23] compared to poor metabolizers (P = .038) and extensive metabolizers (P = .011), intermediate metabolizers had significantly higher hot flash severity score after 4 months of tamoxifen treatment. Here, CYP2D6 is linked to breast cancer.